Drug intelligence / Profile preview

anti-csbD bovine immunoglobulin G

Development stage: Phase 2
Lead developer: Johns Hopkins Bloomberg School of Public Health
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

Anti-CsbD bovine immunoglobulin G is a hyperimmune bovine milk immunoglobulin product specifically targeting CsbD, which is a minor fimbrial adhesin component of CS17 fimbriae found in enterotoxigenic Escherichia coli (ETEC). It is designed to provide passive immunity against ETEC-induced diarrhea when administered orally. The product works by binding to the CsbD adhesin, potentially preventing bacterial attachment to intestinal cells and inhibiting colonization.

Other names: Anti-CsbD Bovine IgGAnti-CsbD bovine milk IgG

Targets

CS17 (Coli surface antigen 17)

Beyond the preview

Go deeper on anti-csbD bovine immunoglobulin G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-csbD bovine immunoglobulin G.

Explore the full profile